Clinical trial Phase 3 Interventional Ages 18 to 130

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Run by AstraZeneca · NCT05629585 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-09-01.

This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.

Research outlook What's coming for Triple-negative breast cancer: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 130 Years
SexAll
Enrollment1174 (actual)
SponsorAstraZeneca
Industry-sponsored
Drugs / interventionsDato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Locations276 sites (Belgium, Brazil, Canada, China, Denmark, France, Germany, Greece and more)
Trial IDNCT05629585 on ClinicalTrials.gov

What this trial studies

The study will investigate the efficacy and safety of Dato-DXd with or without durvalumab when compared with ICT (capecitabine and/or pembrolizumab) in participants with stage I to III TNBC who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy. The primary objective of the study is to demonstrate superiority of Dato-DXd in combination with durvalumab relative to ICT by assessment of iDFS in participants with stage I to III TNBC with residual invasive disease at surgical resection following neoadjuvant therapy.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Participant must be ≥ 18 years at the time of screening.
2. Histologically confirmed invasive TNBC, as defined by the ASCO/CAP guidelines.
3. Residual invasive disease in the breast and/or axillary lymph node(s) at surgical resection following neoadjuvant therapy.
4. Completed at least 6 cycles of neoadjuvant therapy containing an anthracycline and/or a taxane with or without platinum chemotherapy, with or without pembrolizumab.
5. No evidence of locoregional or distant relapse.
6. Surgical removal of all clinically evident disease in the breast and lymph nodes.
7. ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to randomisation.
8. All participants must provide an FFPE tumour sample from residual invasive disease at surgery for tissue-based analysis.
9. No adjuvant systemic therapy.
10. Radiotherapy (if indicated) delivered before the start of study intervention.
11. If post-operative radiation therapy is given, an interval of no more than 6 weeks between the completion of radiation therapy and the date of randomisation (radiation therapy can be completed during screening period). If no post-operative radiation therapy is given, an interval of no more than 16 weeks between the date of breast surgery and the date of randomisation.
12. Has LVEF ≥ 50% by either an ECHO or MUGA scan within 28 days before randomisation.
13. Eligible for one of the therapy options listed as investigator's choice per investigator assessment.
14. No known germline BRCA1 or BRCA2 pathogenic mutation.
15. Adequate bone marrow reserve and organ function within 7 days before randomisation.

Exclusion Criteria:

1. Stage IV (metastatic) TNBC.
2. History of prior invasive breast cancer, or evidence of recurrent disease following preoperative therapy and surgery.
3. Severe or uncontrolled medical conditions including systemic diseases, history of allogeneic organ transplant and active bleeding diseases, ongoing or active infection, serious chronic gastrointestinal conditions associated with diarrhea chronic diverticulitis or previous complicated diverticulitis.
4. History of another primary malignancy except for adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ disease (including ductal carcinoma in situ) that has undergone potentially curative therapy, or other solid malignancy treated with curative intent with no known active disease within 5 years before randomisation and of low potential risk for recurrence.
5. Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss).
6. Active or prior documented autoimmune or inflammatory disorders.
7. Clinically significant corneal disease.
8. Active or uncontrolled hepatitis B or C virus infection.
9. Known HIV infection that is not well controlled
10. Active tuberculosis infection.
11. Mean resting corrected QTcF \> 470 ms regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.
12. Uncontrolled or significant cardiac disease.
13. History of non-infectious ILD/pneumonitis including radiation, pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
14. Has severe pulmonary function compromise.
15. Any known active liver disease.
16. Grade ≥ 2 peripheral neuropathy of any aetiology.
17. Prior exposure to a PD-1/PD-L1 inhibitor other than pembrolizumab.
18. Current or prior use of immunosuppressive medication within 14 days prior to randomisation.
19. Participants with a known severe hypersensitivity to Dato-DXd or any of the excipients of these products including but not limited to polysorbate 80 or other monoclonal antibodies.
20. Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors.
21. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation, randomisation into a prior Dato-DXd, T-DXd, or durvalumab study regardless of treatment assignment.
22. Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.

Where it's running

  • Research Site
    Gilbert, Arizona, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Hot Springs, Arkansas, United States
  • Research Site
    Little Rock, Arkansas, United States
  • Research Site
    Springdale, Arkansas, United States
Show 44 more locations
  • Research Site
    Beverly Hills, California, United States
  • Research Site
    Costa Mesa, California, United States
  • Research Site
    Duarte, California, United States
  • Research Site
    Fountain Valley, California, United States
  • Research Site
    Irvine, California, United States
  • Research Site
    La Jolla, California, United States
  • Research Site
    Lakewood, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Newport Beach, California, United States
  • Research Site
    Newport Beach, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    Roseville, California, United States
  • Research Site
    Upland, California, United States
  • Research Site
    Vallejo, California, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    New Haven, Connecticut, United States
  • Research Site
    Newark, Delaware, United States
  • Research Site
    Washington D.C., District of Columbia, United States
  • Research Site
    Altamonte Springs, Florida, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Miami Beach, Florida, United States
  • Research Site
    Tallahassee, Florida, United States
  • Research Site
    West Palm Beach, Florida, United States
  • Research Site
    Athens, Georgia, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Maywood, Illinois, United States
  • Research Site
    Westwood, Kansas, United States
  • Research Site
    Lexington, Kentucky, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    New Orleans, Louisiana, United States
  • Research Site
    Annapolis, Maryland, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Columbia, Maryland, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    St Louis, Missouri, United States
  • Research Site
    Camden, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    New York, New York, United States

+226 more sites. See ClinicalTrials.gov for the full list.

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.